Results 101 to 110 of about 265,599 (259)
Biotechnology Progress, EarlyView.Abstract Artificial intelligence and automation are no longer just buzzwords in the biopharmaceutical industry. The manufacturing of a class of biologics, comprising monoclonal antibodies, cell therapies, and gene therapies, is far more complex than that of traditional small molecule drugs.
Shyam Panjwani, Hao Wei, John Mason
wiley +1 more source
Effect of cell retention techniques in Komagataella phaffii lab‐scale continuous processes
Biotechnology Progress, EarlyView.Abstract Perfusion technologies play a growing role in the implementation of continuous processes for biotherapeutics production in mammalian‐based manufacturing. However, their application to alternative production hosts is limited. Cell retention systems are of key importance for the efficiency of perfusion bioreactors.
Marina Y. Linova +5 more
wiley +1 more source
Enhancing CHO cell recombinant protein production using a perfusion‐directed host evolution approach
Biotechnology Progress, EarlyView.Abstract Clonally derived cell lines generated from Chinese hamster ovary (CHO) cells encounter numerous stressors when cultured in high‐intensity perfusion bioreactors leading to poor process performance. To circumvent this, the ability of CHO cells to adapt to different culture environments was exploited. Here host cells were selected in the presence
Peter Amaya +7 more
wiley +1 more source
Biotechnology Progress, EarlyView.Abstract Scaled production of cultivated meat (CM) will co‐produce large volumes of spent media. Recycling of abundant metabolites such as lactic acid in spent media offers an opportunity for valorization and reduction of the carbon footprint of CM production; however, the feasibility has yet to be examined.
Josh Wimble +2 more
wiley +1 more source
Dynamics of natural killer cell function upon recurrent stimulation
Biotechnology Progress, EarlyView.Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One +4 more
wiley +1 more source
Biotechnology Progress, EarlyView.Abstract A rapid assessment of manufacturability for drug candidates is crucial for advancing a prospective biotherapeutic from a candidate to a bulk drug substance. A lot‐to‐lot approach to manufacturability is adopted where each biologic batch is assessed for manufacturability as a bulk, unfractionated pool.
Solomon Isu +6 more
wiley +1 more source
Veterinary Clinics of North America: Exotic Animal Practice, 2005 Kanki, Phyllis J., Essex, Myron E.
openaire +2 more sources
Biotechnology Progress, EarlyView.Abstract As adeno‐associated viral vectors (AAV) continue to advance through the clinical pipeline, effective downstream purification strategies must be developed to ensure bulk drug purity and safety. AAV are produced within mammalian cells, bringing forth risks associated with viral contamination.
Akshay S. Chaubal +5 more
wiley +1 more source
Biotechnology Progress, EarlyView.For biofuels production, hemicellulose pre‐hydrolysate is considered as an attractive feedstock rich in fermentable sugars. The pre‐hydrolysate derived from lignocellulosic biomass comprises, along with sugars, several inhibitors which can hamper its efficient conversion.
Mariem Theiri +3 more
wiley +1 more source